Australian Company to lead international research into cannabis (CBD) products and medication.

Media Release

Published by New Realm Media

26th June 2019

Medicinal Organic Cannabis Australia (MOCA) Pty Ltd, a federally licenced Medical Cannabis company in Australia has commissioned and initiated a clinical study on CBD and its use internationally. The research is designed to understand and interpret the usage patterns and motivations of CBD users and its role in the health supplement industry.

Dr Eliane Karsaklian, a senior professor at the prestigious Sorbonne (University of Paris) and visiting professor at the University of Chicago leads the research team.

CBD or Cannabidiol is a cannabinoid found in the cannabis plant. CBD has drawn significant attention in recent years as a health supplement and medicine that can assist with a number of health conditions. Recognized as the second most prevalent of the active ingredients of cannabis (marijuana), CBD is a component of marijuana that does not cause a “high.” In both animal and human trials, CBD has shown substantial evidence that it could be a powerful anti-anxiety therapy

The World Health Organization reported, “In humans, CBD exhibits no effects indicative of any abuse or dependence potential…. To date, there is no evidence of public health related problems associated with the use of pure CBD.”

The evidence for cannabidiol health benefits is significant and constantly growing; CBD is used for a wide variety of health issues including childhood epilepsy syndromes, such as Dravet syndrome and Lennox-Gastaut syndrome (LGS). CBD is commonly used to treat anxiety, and for patients who suffer insomnia, studies suggest that CBD may help with both falling asleep and staying asleep.

Another major benefit of CBD is that it may offer an option for treating different types of chronic pain.

Medicinal Organic Cannabis Australia (MOCA)’s CEO, Alessandro Sorbello, an international award-winning researcher said “…the research is much needed to better understand how CBD fits into the medical framework. In the United States, CBD is sold over the counter and is widely available; you can find it in a myriad of products from beverages to gummy bears. This Australian led scientific research involves academics based in Europe, the United States, Australia, and Asia and will run over the next 6 months and will encompass tens of thousands of CBD users".

The results of the study will be made publicly available and published in mid-2020.